# NVCT (Nuvectis Pharma, Inc.) - SEC EDGAR Financial Statements

> Nuvectis Pharma, Inc. reported $140.8M in total assets and a net loss of $50.45M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/NVCT
- Markdown: https://convexityos.com/fundamentals/NVCT.md
- SEC CIK: 0001875558
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:33 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001875558&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$52.12M | Operating profit |
| Net Income | FY 2025 | -$50.45M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.71 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $140.7M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Research & Development | $18.15M | $12.92M | $15.38M | $13.23M | $9.54M |
| **Operating Income** | -$27.57M | -$19.85M | -$22.90M | -$19.23M | -$12.89M |
| **Net Income** | -$26.44M | -$19.00M | -$22.26M | -$19.09M | -$12.89M |
| Basic EPS | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
| **Diluted EPS** | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
| Basic Shares Outstanding | 21.8M | 17.1M | 15.6M | 12.7M | 4.3M |
| Diluted Shares Outstanding | 21.8M | 17.1M | 15.6M | 12.7M | 4.3M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $27.37M | $4.68M | $4.11M | $5.09M | $5.77M | $3.61M | $3.68M | $4.50M |
| **Operating Income** | -$31.05M | -$7.20M | -$6.26M | -$7.62M | -$7.79M | -$6.59M | -$5.57M | -$6.45M |
| **Net Income** | -$30.07M | -$7.02M | -$6.05M | -$7.31M | -$7.46M | -$6.33M | -$5.33M | -$6.25M |
| Basic EPS | -$1.02 | -$0.30 | -$0.26 | -- | -$0.44 | -$0.30 | -$0.27 | -- |
| **Diluted EPS** | -$1.02 | -$0.30 | -$0.26 | -- | -$0.44 | -$0.30 | -$0.27 | -- |
| Basic Shares Outstanding | 29.5M | 23.5M | 23.4M | -- | 22.7M | 21.4M | 19.9M | -- |
| Diluted Shares Outstanding | 29.5M | 23.5M | 23.4M | -- | 22.7M | 21.4M | 19.9M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $31.63M | $18.53M | $19.13M | $19.99M | $5.74M |
| **Cash & Short-Term Investments** | $31.63M | $18.53M | $19.13M | $19.99M | $5.74M |
| Other Current Assets | $75K | $74K | $59K | $412K | $91K |
| **Total Current Assets** | $31.71M | $18.61M | $19.18M | $20.41M | $5.83M |
| **Total Non-Current Assets** | $0 | $0 | $0 | $0 | $824K |
| **Total Assets** | $31.71M | $18.61M | $19.18M | $20.41M | $6.66M |
| Accounts Payable | $6.27M | $2.50M | $2.77M | $2.91M | $1.06M |
| **Total Current Liabilities** | $13.30M | $8.89M | $6.98M | $6.19M | $2.42M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $13.30M | $8.89M | $6.98M | $6.19M | $2.42M |
| Retained Earnings | -$99.69M | -$73.25M | -$54.24M | -$31.98M | -$12.90M |
| **Total Stockholders' Equity** | $18.41M | $9.71M | $12.20M | $14.22M | -$11.01M |
| Total Equity | $18.41M | $9.71M | $12.20M | $14.22M | -$11.01M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $140.7M | $22.16M | $25.13M | $31.63M | $35.44M | $26.79M | $29.86M | $18.53M |
| **Cash & Short-Term Investments** | $140.7M | $22.16M | $25.13M | $31.63M | $35.44M | $26.79M | $29.86M | $18.53M |
| Other Current Assets | $132K | $216K | $268K | $75K | $145K | $214K | $284K | $74K |
| **Total Current Assets** | $140.8M | $22.38M | $25.40M | $31.71M | $35.59M | $27.01M | $30.15M | $18.61M |
| **Total Non-Current Assets** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Assets** | $140.8M | $22.38M | $25.40M | $31.71M | $35.59M | $27.01M | $30.15M | $18.61M |
| Accounts Payable | $5.76M | $5.18M | $4.70M | $6.27M | $6.44M | $4.98M | $2.99M | $2.50M |
| **Total Current Liabilities** | $14.19M | $13.29M | $11.18M | $13.30M | $11.58M | $10.13M | $9.19M | $8.89M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $14.19M | $13.29M | $11.18M | $13.30M | $11.58M | $10.13M | $9.19M | $8.89M |
| Retained Earnings | -$142.8M | -$112.8M | -$105.7M | -$99.69M | -$92.37M | -$84.91M | -$78.58M | -$73.25M |
| **Total Stockholders' Equity** | $126.6M | $9.08M | $14.22M | $18.41M | $24.01M | $16.87M | $20.95M | $9.71M |
| Total Equity | $126.6M | $9.08M | $14.22M | $18.41M | $24.01M | $16.87M | $20.95M | $9.71M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$26.44M | -$19.00M | -$22.26M | -$19.09M | -$12.89M |
| Stock-Based Compensation | $6.03M | $4.86M | $4.71M | $1.71M | $1.89M |
| Change in Payables | $3.78M | -$273K | -$139K | $1.85M | -- |
| **Operating Cash Flow** | -$16.01M | -$12.25M | -$15.95M | -$13.56M | -$9.50M |
| **Investing Cash Flow** | -- | $0 | $0 | $0 | -- |
| Common Stock Issued | -- | $12.04M | $5.29M | -- | -- |
| **Financing Cash Flow** | $29.11M | $11.65M | $15.09M | $27.81M | $15.25M |
| **Net Change in Cash** | $13.10M | -$593K | -$867K | $14.25M | $5.74M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$30.07M | -$7.02M | -$6.05M | -$7.31M | -$7.46M | -$6.33M | -$5.33M | -$6.25M |
| Stock-Based Compensation | $2.42M | $1.71M | $1.85M | $1.48M | $1.46M | $1.73M | $1.37M | $1.14M |
| Change in Payables | $577K | $489K | -$1.58M | -$165K | $1.46M | $1.99M | $494K | $237K |
| **Operating Cash Flow** | -$25.28M | -$4.53M | -$6.51M | -$3.97M | -$4.49M | -$3.37M | -$4.17M | -$2.46M |
| **Investing Cash Flow** | -- | -- | $0 | -- | -- | -- | $0 | -- |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | -- | $3.95M |
| **Financing Cash Flow** | $143.8M | $1.56M | $7.0K | $166K | $13.14M | $296K | $15.51M | $3.83M |
| **Net Change in Cash** | $118.5M | -$2.97M | -$6.50M | -$3.81M | $8.65M | -$3.07M | $11.33M | $1.36M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -143.6% | -195.6% | -182.4% | -134.2% | -- |
| Return on Assets (ROA) | -83.4% | -102.1% | -116.0% | -93.5% | -193.6% |
| Current Ratio | 2.38x | 2.09x | 2.75x | 3.30x | 2.41x |
| Quick Ratio | 2.38x | 2.08x | 2.74x | 3.23x | 2.37x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -39.8% | -306.6% | -191.0% | -143.6% | -105.7% | -130.8% | -96.2% | -195.6% |
| Return on Assets (ROA) | -35.8% | -124.4% | -106.9% | -83.4% | -71.3% | -81.7% | -66.9% | -102.1% |
| Current Ratio | 9.92x | 1.68x | 2.27x | 2.38x | 3.07x | 2.66x | 3.28x | 2.09x |
| Quick Ratio | 9.91x | 1.67x | 2.25x | 2.38x | 3.06x | 2.64x | 3.25x | 2.08x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
